Form 4: BeOne Medicines CEO John Oyler Reports Routine Share Sales for Tax Withholding

BeOne Medicines Ltd. CEO John Oyler reported sales of American Depositary Shares on June 16 and June 17, 2025, primarily to cover mandatory tax withholding obligations related to restricted share unit vesting.

Summary

• John Oyler, the Chief Executive Officer and a Director of BeOne Medicines Ltd. (ONC), reported two separate sales of American Depositary Shares (ADSs).
• On June 16, 2025, Mr. Oyler sold 3,680 ADSs at a weighted average price of $266.0452 per ADS. The individual transaction prices ranged from $265.705 to $266.57.
• On June 17, 2025, an additional 1,460 ADSs were sold at a weighted average price of $256.4885 per ADS, with prices ranging from $256.17 to $256.88.
• Both sales were conducted to satisfy mandatory tax withholding provisions associated with the vesting of previously granted restricted share unit (RSU) awards.
• Each American Depositary Share represents 13 Ordinary Shares of BeOne Medicines Ltd.
• Following these transactions, John Oyler's direct beneficial ownership of American Depositary Shares is 0.
• Mr. Oyler's indirect beneficial ownership includes 28,204,115 Ordinary Shares held for his benefit in a Roth IRA PENSCO trust account.
• He disclaims beneficial ownership for 8,215,021 Ordinary Shares held by the P&O Trust, 481,533 Ordinary Shares in a grantor retained annuity trust, 7,722,480 Ordinary Shares by Oyler Investment LLC, and 9,545,000 and 102,188 Ordinary Shares by The John Oyler Legacy Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the sales are for mandatory tax withholding, a routine event for executive compensation, rather than a discretionary sale indicating a change in confidence or outlook.

Positives

• The sales were explicitly for mandatory tax withholding, indicating a routine and non-discretionary transaction rather than a sale driven by a change in management's confidence.
• The vesting of restricted share units signifies that previously granted equity compensation is maturing, which is a positive aspect of executive compensation.

Negatives

• The transactions result in a reduction of the CEO's direct shareholdings, although this is a common occurrence for tax purposes related to equity compensation.

Future Outlook

The document indicates ongoing vesting schedules for restricted share units, with 1/4th of securities vesting annually from June 15, 2023, and June 16, 2021, respectively, subject to continued service. Unvested securities are subject to accelerated vesting upon a change of control or certain termination events.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, specifically sales for tax withholding purposes. Such transactions are common in the industry as executives' equity compensation vests, and they are required to cover tax liabilities. It does not provide broader industry trends or competitive insights.

Related Party Transactions

• Securities held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.
• Securities held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
• Securities held by Oyler Investment LLC, of which 99% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
• Securities held by The John Oyler Legacy Trust for the benefit of the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership.

Stakeholder Impact

• Shareholders: The sales represent a minor reduction in direct insider ownership, but as they are for tax purposes, they typically do not signal a change in management's outlook. The disclosure provides transparency regarding executive compensation and holdings.
• Employees: The vesting of RSUs is part of the company's equity compensation program, which can be a positive for employee retention and alignment with shareholder interests.

Next Steps

• Continued vesting of restricted share units on each anniversary of June 15, 2023, and June 16, 2021, subject to continued service.
• Potential accelerated vesting of unvested securities upon a change of control or certain termination events.

Key Dates

Keywords

BeOne Medicines Ltd., ONC, John Oyler, SEC Form 4, Insider Trading, Stock Sale, Restricted Share Units, Tax Withholding, American Depositary Shares, CEO, Director, Equity Compensation